iShares Genomics Immunology and Healthcare ETFIDNA
Type
ETF
Peer group
Global equity
Net assets
$160.5M
Expense ratio
0.47%
1-year return
+41.5%
3 years, a year
+9.0%
5 years, a year
-8.5%
Holdings
63
What it aims to do.
The iShares Genomics Immunology and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 20.98% |
| RVMD Revolution Medicines, Inc. | 6.85% |
| MRNA Moderna, Inc. | 6.28% |
| Ipsen Sa | 5.24% |
| Bayer Aktiengesellschaft | 4.38% |
| Takeda Pharmaceutical Company Limited | 4.22% |
| MRK Merck & Co., Inc. | 4.15% |
| Gsk Plc | 4.12% |
| BNTX BioNTech SE | 4.07% |
| Roche Holding AG | 3.99% |
More on IDNA.
- IDNA overview
- IDNA holdings
- IDNA risk
- IDNA costs
- IDNA money in and out
- IDNA share classes
- Compare IDNA with other funds
Returns after fees, from the fund's SEC filings up to Apr 2026. Past returns are not a promise. Not financial advice.